DNA vaccination provides a novel method to induce both humoral and cell-mediated immunities (8, 31) . The simplicity of the technology, its ability to induce antibody (Ab) and cytotoxic T-lymphocyte (CTL) responses in animals with different genetic backgrounds, and its preclinical efficacy in a variety of disease models (5, 7, 18, 31, 33) suggest that DNA vaccination may be a useful approach for vaccine development. Additionally, the ability of DNA vaccines to induce immune responses with nonreplicating materials offers an alternative to live vectors or pathogens for eliciting cell-mediated immunity for those instances where such agents may present potential safety concerns. In a previous study from our laboratory, we demonstrated that intramuscular injection of a plasmid DNA encoding influenza virus nucleoprotein (NP) induced a vigorous CTL response specific for an H-2K d -restricted epitope 147-155 in BALB/c mice (31) . Furthermore, immunization with NP DNA, in which the sequence coding for NP was derived from influenza virus A/PR/8/34 (H1N1), conferred protection against a lethal dose challenge with the influenza virus A/HK/68 (H3N2), wherein much of the NP sequence including the H-2K d -restricted CTL epitope 147-155 was conserved, despite a very significant antigenic difference in viral surface glycoproteins. In this report, we sought to address the following issues concerning the immunological and protective mechanisms of DNA vaccines: (i) whether a DNA vaccine permits epitope determinant selection to occur for the induction of CTL responses restricted by different haplotypes; (ii) whether in vivo cross-strain protection is mediated by the cellular immunity induced by a DNA vaccine encoding a conserved viral internal antigen; (iii) whether the cell-mediated protective immunity is solely dependent on the CTL response against an immunodominant epitope; and (iv) whether DNA immunization can induce major histocompatibility complex (MHC) class I molecule-restricted CTL responses against epitopes other than the immunodominant epitope. CD8 ϩ T cells recognize viral antigens in the form of short peptides presented by MHC class I molecules on the surface of virus-infected cells (2, 30, 34) . The recognition of these viral peptides in the context of MHC molecules by CD8 ϩ T cells can trigger the specific lysis of virally infected cells (4, 19) or noncytopathic intracellular inactivation of virus mediated by cytokines such as gamma interferon and tumor necrosis factor ␣ (15, 16) . CD8
ϩ CTL have thus been implicated as playing a role in recovery or clearance of virus during a viral infection (6, 21, 22) . Additionally, a role for CD4 ϩ T cells in resistance to influenza virus was indicated by experiments using ␤2-microglobulin gene knockout (␤2M Ϫ/Ϫ ) mice which are defective in expressing MHC class I molecules on the cell surface and lack functional CD8 ϩ T cells or using monoclonal antibodies to in vivo deplete the CD8 ϩ T-cell population. Several groups of investigators reported that the ␤2M Ϫ/Ϫ or CD8 ϩ -depleted mice could recover from influenza virus infection, though in a delayed fashion in some instances (1, 9, 10, 20) . Thus, it appears that cellular immune responses, mediated by either CD8 ϩ or CD4 ϩ T cells, are important for recovery from influenza virus infection.
In this study, we generated a cDNA expression vector encoding a mutant version of full-length NP in which the anchor residues for the NP147-155 CTL epitope were altered. By immunizing mice with the mutant version of NP DNA, we identified an immunorecessive CTL epitope in NP, residues 218 to 226, and showed that BALB/c mice immunized with the mutant NP DNA are resistant to cross-strain virus challenge. Furthermore, the resistance to cross-strain influenza virus challenge induced by the mutant form of NP DNA, like that induced by a cDNA immunization vector encoding wild-type NP, can be adoptively transferred to unprimed mice with the immune lymphocytes.
MATERIALS AND METHODS
Synthetic peptides and oligonucleotides. All synthetic peptides were custom synthesized by Chiron-Mimotopes, Inc., Raleigh, N.C., and their sequences are summarized in Table 1 . The mutagenesis and sequencing oligonucleotides were synthesized by the Midland Certified Reagent Company, Midland, Tex.
DNA constructs. The expression vector used in the study, V1Ja, was derived from the vector V1J, which has been described previously (23) . Briefly, it contains the human cytomegalovirus immediate-early gene enhancer and promoter, the intron A sequence, multiple restriction sites for cloning the gene of interest, and bovine growth hormone polyadenylation sequence. The NP gene from in-fluenza virus A/PR/8/34 (H1N1) was cloned into the BglII and SalI sites. To generate the NPmut construct which contains two point mutations within the H-2K d -restricted CTL epitope (residues 147 to 155), the NP DNA fragment was cloned into pAlterSite vector from Promega Corp., Madison, Wis. The mutagenesis was achieved by using an AlterSite kit purchased from Promega. The plasmid DNA used for immunization was purified from Escherichia coli by a modified alkaline lysis procedure, and DNA was banded twice in a CsCl 2 gradient (29) .
Animals. Four-to eight-week-old female BALB/c or C57BL/6 mice were purchased from Charles River Laboratories, Raleigh, N.C. The animals were maintained in the animal facility of Merck Research Laboratories at West Point, Pa. All experiments were performed in accordance with the procedures issued by International Animal Care and Use Committee.
Immunization, challenge, and adoptive transfer protocol. For immunization, mice under anesthesia induced by the administration of ketamine-xylazine were injected with 100 g of DNA dissolved in 100 l of sterile saline three times at 3-week intervals. Fifty microliters of DNA was injected bilaterally into the quadriceps muscle each time. To prime mice with live influenza virus A/PR/8/34, mice were infected intranasally while awake (13) . For challenge studies, mice were fully anesthetized and intranasally inoculated with 20 l containing a mouseadapted strain, A/HK/68 (H3N2). This challenge dose has been characterized as 10 2.5 50% tissue culture infective doses, 300 50% mouse infective doses, or about 10 50% lethal doses. This routinely results in 90% death in unimmunized mice (13, 31) . Survival and body mass of the challenged mice were monitored for up to 4 weeks.
The adoptive transfer protocol was modified from a method described by Wells et al. (32) . The spleen cells harvested from the donor mice were cultured and restimulated for 6 or 7 days with syngeneic cells that had been either infected with A/PR/8/34 virus or pulsed with synthetic peptides. Interleukin-2 (IL-2; Cellular Products Inc., Buffalo, N.Y.) was added 10 U/ml on the second day of culture. Lymphocytes were washed three times with phosphate-buffered saline and resuspended at desired concentrations in phosphate-buffered saline. The recipient mice, 4 h after challenge infection with influenza virus A/HK/68, received 0.2-ml volume of lymphocytes (5 ϫ 10 7 cells/mouse) through the tail veins, which had been dilated in hot water (about 50ЊC). The survival and weight loss were monitored for up to 4 weeks.
Cells and CTL cultures. P815 (H-2 d ) and EL4 (H-2 b ) cells, routinely used as target cells for the cytotoxicity assay, were maintained in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin per ml, 100 g of streptomycin per ml, 5 mM HEPES, and 0.0225% sodium bicarbonate. All cell culture reagents were purchased from GIBCO/BRL Life Technologies, Grand Island, N.Y.
Spleen cells were cultured to generate effector CTL as previously described (31) . Spleen cell cultures were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol, 25 g of pyruvic acid per ml, 100 U of penicillin per ml, 100 g of streptomycin per ml, 5 mM HEPES, and 0.0225% sodium bicarbonate. Irradiated syngeneic cells, either pulsed with peptide (10 M) or infected with A/PR/8/34 virus, were used as stimulator cells. Unless specified, no IL-2 was added in the first round of in vitro restimulation. Long-term CTL cultures were maintained in complete RPMI 1640 medium plus 10 U of recombinant human IL-2 per ml.
The CD4 ϩ and CD8 ϩ T-cell subset enrichments were performed by using T-cell subset purification columns (Biotex Laboratories, Inc., Edmonton, Alberta, Canada). Briefly, splenocyte suspensions from mice immunized with DNA were washed and incubated with the monoclonal Abs supplied with the column. These Ab preparations consist of monoclonal Abs directed against surface marker antigens of B cells and of the T-cell subset which is intended to be depleted. The cells were then passed through a column of glass beads coated with anti-mouse immunoglobulin G which bound the cells coated with Abs. The unbound cells, the majority of which were the desired T-cell subset, were eluted from the column and collected. The purity of CD4 ϩ or CD8 ϩ lymphocytes was confirmed by FACScan analysis.
Cytotoxicity assay. The cytotoxicity assays were performed as described previously (31) . Briefly, target cells labeled with Na 51 CrO 4 (Amersham Life Sciences, Arlington Heights, Ill.) were either infected with influenza virus A/Victoria (Vic)/73 (H3N2) or pulsed with synthetic peptides at the indicated concentration. The target cells were then mixed with CTLs at designated effector/target cell ratios in 96-well plates and incubated at 37ЊC for 4 h in the presence of 5% CO 2 . A 20-l sample of supernatant from each cell mixture was counted to determine the amount of 51 Cr released from target cells. The percentage of specific lysis was calculated by using the formula % specific lysis ϭ
, where E represents the average counts per minute released from target cells in the presence of effector cells, S is the spontaneous counts per minute released in the presence of medium only, and M is the maximum counts per minute released in the presence of 5% sodium dodecyl sulfate or 2% Triton X-100.
RESULTS
Generating the NPmut DNA construct. Two significant point mutations, in terms of both amino acid size and charge, were introduced into the NP147-155 CTL epitope sequence at the putative anchor positions (11, 28) . The resultant DNA construct, named NPmut, encoded a full-length NP with these two mutations. The H-2D b -restricted CTL epitope 366-374 remained intact in the NPmut construct ( Fig. 1) . A synthetic peptide corresponding to the mutant epitope sequence, NP147-155mut peptide, was prepared (peptide sequences are shown in Table 1 Characterization of the cytotoxicity seen in NPmut DNAimmunized mice. To determine whether the cytolytic activity seen in the spleen cells from NPmut DNA-immunized mice included a CD8
ϩ CTL response, we enriched the T-cell population for either CD8 ϩ or CD4 ϩ T-cell subsets from the mice immunized with NP DNA or NPmut DNA. The enriched T cells were restimulated in vitro with syngeneic cells infected with A/PR/8/34 influenza virus for 7 days and used as effector cells in the 4-h cytotoxicity experiment depicted in Fig. 4 . The enriched CD4
ϩ T-cell cultures were included as a control. As shown in Fig. 5 , the CD8 ϩ T cells derived from the mice immunized with NP DNA recognized both virus-infected and NP147-155 peptide-pulsed targets, and the CD8 ϩ T cells from the mice immunized with NPmut DNA lysed only the virusinfected target cells. As expected, no cytotoxicity against either virus-infected or NP147-155 peptide-pulsed targets was detected in the control CD4 
CD8
ϩ T cells from mice immunized with vector control DNA likewise did not recognize any target cells. The CD8 ϩ T cells derived from the mice immunized with NP DNA recognized both virus-infected and NP147-155 peptide-pulsed targets, and the CD8 ϩ T cells from the mice immunized with NPmut DNA lysed only the virus-infected target cells. These data demonstrated that the cytolytic activity induced in BALB/c mice immunized with NPmut DNA, which was directed against a CTL epitope other than the NP147-155 epitope, included a population of CD8 ϩ T cells. Since our experimental conditions were intentionally not optimized for detecting the lytic activity of CD4 ϩ cells, the existence of a CD4 ϩ CTL component also is possible.
Identification of an immunorecessive CTL epitope in NP. Most H-2K d
-binding peptides identified to date contain a tyrosine at the second position and a hydrophobic residue at the C terminus to serve as two major anchor residues (11, 28) . Therefore, we scanned the amino acid sequence of NP and selected three peptides with this consensus H-2K d -binding motif. Since the peptide corresponding to NP residues 39 to 47 was unable to be synthesized due to high hydrophobicity, we tested only the two synthetic peptides corresponding to NP110-119 and NP218-226 ( Table 1 ). As shown in Table 2 , virusrestimulated CTL from mice immunized with NP DNA or NPmut DNA recognized target cells infected with A/Vic/73 virus, whereas only the NP DNA-induced CTL could lyse the target cells pulsed with NP147-155 peptide. NP110-119 peptide-pulsed target cells were not recognized by either NP DNA-or NPmut DNA-induced CTL. However, target cells sensitized with NP218-226 peptide were specifically killed by NPmut DNA-induced CTL. In contrast, the NP DNA-induced CTL did not lyse the NP218-226 peptide-pulsed cells. Thus, NP218-226 behaves as a typical immunorecessive epitope in that the CTL response against this epitope can be detected only when the immunodominant CTL epitope, NP147-155, is absent from the immunogens used to prime CTL precursors in vivo (24) (25) (26) .
The NP218-226 CTL epitope overlaps with a Th epitope (residues 216 to 229) identified earlier in BALB/c mice (14) . Therefore, to confirm that the epitope that we identified was indeed an H-2K d -binding peptide, we performed a peptide competition assay. We used CTL cultures from NP DNA-or NPmut DNA-immunized mice to lyse the target cells sensitized by the two peptides, since the recognition of NP147-155 and that of NP218-226 epitopes by the NP DNA-and NPmut DNA-induced CTL were shown to be mutually exclusive (Table 2). NP147-155 peptide at a constant concentration (1 nM) was mixed with increasing concentrations of NP218-226 peptide. Target cells, pulsed with the mixture of peptides, were incubated with the CTL cultures described above. As shown in encoding the wild-type NP sequence provided protection against death and morbidity following a lethal-dose influenza virus challenge (31) . Since this method of immunization induced a robust CTL response against the NP147-155 epitope, we sought to determine whether the NPmut DNA immunization could still provide protection against the cross-strain challenge with A/HK/68 (H3N2) in the absence of the CTL response to NP147-155 epitope. As shown in Fig. 7 , like the mice immunized with NP DNA, all of the BALB/c mice intramuscularly injected with NPmut DNA three times at 3-week intervals survived challenge, whereas the mice immunized with control vector DNA were susceptible to the virus challenge.
To evaluate the role of cell-mediated immunity in the protection that we observed with DNA immunization, we performed lymphocyte adoptive transfer experiments. Splenocytes from NP DNA-or NPmut DNA-immunized mice were activated in vitro by restimulation with syngeneic spleen cells infected with A/PR/8/34 virus. Spleen cells from mice infected with A/PR/8/34 virus were restimulated in vitro with syngeneic cells infected with A/PR/8/34 virus to serve as positive control, and spleen cells from mice injected with human immunodeficiency virus (HIV) gag DNA were stimulated in vitro with syngeneic spleen cells pulsed with Gag193-212 peptide to serve as negative control (12) . The CTL cultures were functionally cytolytic, as indicated by their ability to specifically lyse P815 cells pulsed with NP147-155 peptide or Gag193-212 peptide, respectively (results not shown). The lymphocytes were adoptively transferred into age-matched naive mice (5 ϫ 10 7 cells/ mouse) that had been challenged with influenza virus A/HK/68 4 h previously. As shown in Fig. 8 , mice that received splenocytes from the mice immunized with NP DNA, NPmut DNA, or A/PR/8/34 virus were protected from death, whereas the majority of the mice receiving no treatment or spleen cells from the mice immunized with HIV gag DNA succumbed to challenge.
DISCUSSION
This study was undertaken to evaluate the CTL responses against NP epitopes presented in the context of MHC class I molecules after DNA immunization (31) . We demonstrated that DNA immunization generated CD8 ϩ CTL specific for MHC class I-restricted epitope peptide. Determinant selection for the CTL epitope peptides was observed among different haplotypes, such that even if one haplotype-restricted epitope was altered, an epitope peptide restricted by another allele remained functional (Fig. 3) . By immunizing BALB/c mice with a mutant NP DNA construct in which the NP147-155 CTL epitope was functionally abolished (Fig. 2 and 3) , no CTL response against the NP147-155 epitope was detected. However, a CTL response was induced that was found to be mediated by CD8 ϩ T cells and was directed against an immunorecessive CTL epitope (Fig. 4 and 5) . The epitope, restricted by H-2K d molecules, was identified and mapped to residues 218 to 226 of NP (Table 2) . Although virus-infected cells presented both peptides in the context of H-2K d molecules, spleen cells from BALB/c mice that had been infected with influenza virus in vivo and then restimulated with virus in vitro demonstrated the CTL response only against the immunodominant epitope, NP147-155 (results not shown). Like the immunorecessive CTL epitopes reported by others (24) (25) (26) , the CTL response against NP218-226 could be primed in vivo only when the immunodominant epitope NP147-155 was altered due to sitedirected mutagenesis in the immunizing NP DNA vector (NPmut DNA). Thus, in this aspect of antigen processing and presentation for the induction of CTL responses, DNA immunization appeared to mimic natural viral infection. Hence, DNA vaccines may provide a useful tool to dissect CTL epitopes within viral antigens and define their roles in viral immunity.
The mechanisms underlying the immunorecessive properties of the NP218-226 epitope are yet to be understood. Since both NP147-155 and NP218-226 peptides were presented by influenza virus-infected cells (Table 2) , it appeared that both peptides could be generated and presented by the MHC class I-dependent antigen processing pathway. Thus, it appears unlikely that a complete lack of binding of NP218-226 peptide to class I molecules in the presence of the NP147-155 epitope would account for the former being immunorecessive. However, the relative amounts of the two peptides presented by virus-infected cells and the number of occupied MHC molecules required for cytolysis by the CTL for the two peptides are undetermined. Therefore, the preferential display of one We also demonstrated that immunization with the NPmut DNA construct could still provide full protection in mice against lethal cross-strain challenge (Fig. 7) . Furthermore, NPspecific cellular immunity accounts for the protection against the cross-strain challenge, since the protection could be adoptively transferred into virus-infected naive mice by the immune splenocytes from mice immunized with either NP DNA or NPmut DNA (Fig. 8) . These findings are consistent with our earlier finding that transfer of the anti-NP sera collected from mice immunized with NP DNA into naive mice did not confer protection (31) . It is of interest that NPmut DNA-induced cellular immunity, including a CD8 ϩ CTL response against the NP218-226 epitope, can still be protective in the absence of the normally dominant NP147-155-specific CTL response ( Fig. 7  and 8 ). Both CD8 ϩ and CD4 ϩ T-cell populations are likely important for the cross-strain protection with NP DNA immunization, as observed from in vivo T-cell subset depletion studies. In those studies, anti-CD8
ϩ Ab treatment completely abrogated NP DNA-induced protection, and anti-CD4
ϩ Ab treatment diminished the protection (30a). Moreover, an additional study showed that enriched CD8 ϩ T cells from mice immunized with NP DNA or NPmut DNA, after in vitro restimulation with syngeneic spleen cells infected with A/PR/8 virus, can confer full protection in naive mice when adoptively transferred (13a). The importance of CD8 ϩ T-cell response in the protective immunity induced by NP DNA immunization also was supported by adoptive transfer of the H-2K d -restricted NP147-155 peptide-restimulated splenocytes from mice immunized with NP DNA. These lymphocytes were shown to be fully protective for survival when adoptively transferred into virusinfected naive mice, compared to the 20% survival rate of untreated naive mice (results not shown), indicating that the NP147-155 peptide-specific CD8 ϩ CTL are protective against cross-strain virus challenge. However, direct restimulation of splenocytes from NPmut DNA-immunized mice with NP218-226 peptide in the secondary culture did not result in detectable NP218-226-specific CTL (results not shown), in contrast to restimulation with whole virus, which was effective at expanding NP218-226-specific CTL. This finding, although hindering our effort to demonstrate that the NP218-226 peptide-specific CTL are protective effectors in the lymphocyte adoptive transfer experiment, may indicate the potential mechanism underlying the immunorecessive nature of NP218-226, as demonstrated in a recent study that detection of the weak CTL response against a subdominant CTL epitope in influenza virus hemagglutinin, determined by the limited T-cell precursors, required in vitro restimulation of virus-infected splenocytes followed by restimulation with the synthetic peptide (3).
In summary, we generated a mutant version of NP which functionally abrogated the CTL response against epitope 147-155 in BALB/c mice. We showed that the CTL response against another epitope restricted by different allele remained intact. Moreover, we demonstrated that the cross-strain protection by NP DNA and NPmut DNA immunization, with or without the induction of the dominant NP147-155-specific CTL response, respectively, was mediated through cell-mediated immunity. Furthermore, DNA immunization with the NPmut construct in mice uncovered an H-2K d -restricted immunorecessive epitope (NP218-226). Our studies show that DNA immunization can effectively induce CTL responses in accordance with a hierarchical rank in CTL epitope immunogenicities. This observation also suggests that the pathways of antigen processing and presentation for MHC class I-restricted CTL recognition of viral proteins expressed by DNA immunization parallel those already established for viral infection.
